Impact of Introducing Infliximab Biosimilars on Total Infliximab Consumption and Originator Infliximab Prices in Eight Regions: An Interrupted Time-Series Analysis.
Journal
BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy
ISSN: 1179-190X
Titre abrégé: BioDrugs
Pays: New Zealand
ID NLM: 9705305
Informations de publication
Date de publication:
May 2023
May 2023
Historique:
accepted:
21
02
2023
medline:
22
5
2023
pubmed:
24
3
2023
entrez:
23
3
2023
Statut:
ppublish
Résumé
We aimed to assess whether the introduction of the first infliximab biosimilar was associated with changes in overall infliximab consumption (originator and biosimilars) and price changes to the originator infliximab. An interrupted time series analysis using infliximab sales data from 2010 to 2020 from the IQVIA Multinational Integrated Data Analysis System for eight selected regions: Australia, Canada, Hong Kong, Korea, India, Japan, the UK, and the USA. Quarterly measures of infliximab consumption and list prices were respectively defined as the number of standard units (SU)/1000 inhabitants and as 2020 USA dollars (USD)/SU. Following the introduction of infliximab biosimilars, overall infliximab consumption increased in Australia [immediate change: 0.145 SU/1000 inhabitants (P = 0.014); long-term change: 0.022 SU/1000 inhabitants per quarter (P < 0.001)], Canada [immediate change 0.415 (P = 0.008)], the UK [long-term change 0.024 (P < 0.001)], and Hong Kong [immediate change: 0.042 (P < 0.001)]. The list price of originator infliximab also decreased following biosimilar introduction in Australia [immediate change: - 187.84 USD/SU (P < 0.001); long-term change - 6.46 USD/SU per quarter (P = 0.043)], Canada [immediate change: - 145.58 (P < 0.001)], the UK [immediate change: - 34.95 (P = 0.010); long-term change: - 4.77 (P < 0.001)], and Hong Kong [long-term change: - 4.065 (P = 0.046)]. Consumption and price changes were inconsistent in India, Japan, Korea, and the USA. Introduction of the first infliximab biosimilar was not consistently associated with increased consumption across regions. Additional policy and healthcare system interventions to support biosimilar infliximab adoption are needed.
Identifiants
pubmed: 36952213
doi: 10.1007/s40259-023-00589-3
pii: 10.1007/s40259-023-00589-3
pmc: PMC10195719
doi:
Substances chimiques
Infliximab
B72HH48FLU
Biosimilar Pharmaceuticals
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
409-420Subventions
Organisme : NHMRC Project Grant
ID : 1157506
Organisme : NHMRC Project Grant
ID : 1196900
Organisme : RGC Early Career Scheme, University Grants Committee of Hong Kong
ID : 27603421
Informations de copyright
© 2023. The Author(s).
Références
Curtis JR, Singh JA. Use of biologics in rheumatoid arthritis: current and emerging paradigms of care. Clin Ther. 2011;33(6):679–707.
doi: 10.1016/j.clinthera.2011.05.044
pubmed: 21704234
pmcid: 3707489
Schirrmacher V. From chemotherapy to biological therapy: a review of novel concepts to reduce the side effects of systemic cancer treatment. Int J Oncol. 2019;54(2):407–19.
doi: 10.3892/ijo.2018.4661
pubmed: 30570109
Putrik P, Ramiro S, Kvien T.K, et al. Inequities in access to biologic and synthetic DMARDs across 46 European countries. Ann Rheum Dis. 2014;73(1):198–206.
doi: 10.1136/annrheumdis-2012-202603
pubmed: 23467636
Cohen HP, Blauvelt A, Rifkin RM, et al. Switching reference medicines to biosimilars: a systematic literature review of clinical outcomes. Drugs. 2018;78(4):463–78.
doi: 10.1007/s40265-018-0881-y
pubmed: 29500555
pmcid: 5854749
Komaki Y, Yamada A, Komaki F, et al. Efficacy, safety and pharmacokinetics of biosimilars of anti-tumor necrosis factor-α agents in rheumatic diseases; a systematic review and meta-analysis. J Autoimmun. 2017;79:4–16.
doi: 10.1016/j.jaut.2017.02.003
pubmed: 28209290
Dylst P, Simoens S. Does the market share of generic medicines influence the price level? A European analysis. Pharmacoeconomics. 2011;29(10):875–82.
doi: 10.2165/11585970-000000000-00000
pubmed: 21797288
Mulcahy AW, Hlavka JP, Case SR. Biosimilar cost savings in the United States: initial experience and future potential. Rand Health Q. 2018;7(4):3.
pubmed: 30083415
pmcid: 6075809
Dutta B, Huys I, Vulto AG, et al. Identifying key benefits in European off-patent biologics and biosimilar markets: it is not only about price! BioDrugs. 2020;34(2):159–70.
doi: 10.1007/s40259-019-00395-w
pubmed: 31792843
Aladul MI, Fitzpatrick RW, Chapman SR. Impact of infliximab and etanercept biosimilars on biological disease-modifying antirheumatic drugs utilisation and NHS budget in the UK. BioDrugs. 2017;31(6):533–4.
doi: 10.1007/s40259-017-0252-3
pubmed: 29127626
Kawalec P, Stawowczyk E, Tesar T, et al. Pricing and reimbursement of biosimilars in central and eastern European countries. Front Pharmacol. 2017;8:288.
doi: 10.3389/fphar.2017.00288
pubmed: 28642700
pmcid: 5463127
Brill A, Robinson C. Lessons for the United States from Europe’s biosimilar experience. 2020. Available from: https://biosimilarscouncil.org/wp-content/uploads/2020/06/EuropeBiosimilars_June_2020.pdf . Accessed 15 Feb 2023.
Yazdany J. Failure to launch: biosimilar sales continue to fall flat in the United States. Arthritis Rheumatol. 2020;72(6):870–3.
doi: 10.1002/art.41203
pubmed: 31922346
pmcid: 7255927
IQVIA. The impact of biosimilar competition in Europe 2020. Available from: https://ec.europa.eu/health/sites/default/files/human-use/docs/biosimilar_competition_en.pdf . Accessed 8 Mar 2023.
Kim Y, Kwon HY, Godman B, et al. Uptake of biosimilar infliximab in the UK, France, Japan, and Korea: budget savings or market expansion across countries? Front Pharmacol. 2020;11:970.
doi: 10.3389/fphar.2020.00970
pubmed: 32733238
pmcid: 7363801
Zhai MZ, Sarpatwari A, Kesselheim AS. Why are biosimilars not living up to their promise in the US? AMA J Ethics. 2019;21(8):E668–78.
doi: 10.1001/amajethics.2019.668
pubmed: 31397662
World Health Organization. World Health Organization model list of essential medicines, 21st list. Geneva: World Health Organization; 2019.
Amgen. Biosimilar trends report. 2022. Available from: https://www.amgenoncology.com/assets/USA-CBU-80962.pdf . Accessed 15 Feb 2023.
IQVIA. MIDAS. Available from: https://www.iqvia.com/solutions/commercialization/brand-strategy-and-management/market-measurement/midas . Accessed 8 Oct 2021.
Blais JE, Wei Y, Yap KKW, et al. Trends in lipid-modifying agent use in 83 countries. Atherosclerosis. 2021;328:44–51.
doi: 10.1016/j.atherosclerosis.2021.05.016
pubmed: 34091069
Hsia Y, Sharland M, Jackson C, et al. Consumption of oral antibiotic formulations for young children according to the WHO Access, Watch, Reserve (AWaRe) antibiotic groups: an analysis of sales data from 70 middle-income and high-income countries. Lancet Infect Dis. 2019;19(1):67–75.
doi: 10.1016/S1473-3099(18)30547-4
pubmed: 30522834
Jackson C, Hsia Y, Bielicki JA, et al. Estimating global trends in total and childhood antibiotic consumption, 2011–2015. BMJ Glob Health. 2019;4(1):e001241.
doi: 10.1136/bmjgh-2018-001241
pubmed: 30899565
pmcid: 6407570
Tong X, Li X, Pratt NL, et al. Monoclonal antibodies and Fc-fusion protein biologic medicines: a multinational cross-sectional investigation of accessibility and affordability in Asia Pacific regions between 2010 and 2020. Lancet Reg Health West Pac. 2022;26:100506.
doi: 10.1016/j.lanwpc.2022.100506
pubmed: 35789824
pmcid: 9249810
Brauer R, Alfageh B, Blais JE, et al. Psychotropic medicine consumption in 65 countries and regions, 2008–19: a longitudinal study. Lancet Psychiatry. 2021;8(12):1071–82.
doi: 10.1016/S2215-0366(21)00292-3
pubmed: 34801129
pmcid: 9766760
Ju C, Wei L, Man KKC, et al. Global, regional, and national trends in opioid analgesic consumption from 2015 to 2019: a longitudinal study. Lancet Public Health. 2022;7(4):e335–46.
doi: 10.1016/S2468-2667(22)00013-5
pubmed: 35366408
Penfold RB, Zhang F. Use of interrupted time series analysis in evaluating health care quality improvements. Acad Pediatr. 2013;13(6 Suppl.):S38-44.
doi: 10.1016/j.acap.2013.08.002
pubmed: 24268083
World Bank. Population. 2021. Available from: https://data.worldbank.org/indicator/SP.POP.TOTL . Accessed 8 Mar 2023.
Newey WK, West KD. A simple, positive semi-definite, heteroskedasticity and autocorrelation consistent covariance matrix. Econometrica. 1987;55(3):703–8.
doi: 10.2307/1913610
PharmaBoardroom. Regulation, pricing and reimbursement overview. 2018. Available from: https://pharmaboardroom.com/legal-articles/regulation-pricing-and-reimbursement-india/ . Accessed 5 Oct 2021.
Augustovski F, Beratarrechea A, Irazola V, et al. Patient preferences for biologic agents in rheumatoid arthritis: a discrete-choice experiment. Value Health. 2013;16(2):385–93.
doi: 10.1016/j.jval.2012.11.007
pubmed: 23538191
Bose M, Dutta A. Health financing strategies to reduce out-of-pocket burden in India: a comparative study of three states. BMC Health Serv Res. 2018;18(1):830.
doi: 10.1186/s12913-018-3633-5
pubmed: 30390701
pmcid: 6215655
Kastor A, Mohanty SK. Disease-specific out-of-pocket and catastrophic health expenditure on hospitalization in India: do Indian households face distress health financing? PLoS ONE. 2018;13(5): e0196106.
doi: 10.1371/journal.pone.0196106
pubmed: 29746481
pmcid: 5945043
National Pharmaceutical Pricing Authority. List of price controlled drugs (DPCO 1995). Available from: https://ipapharma.org/list-of-price-controlled-drugs-dpco-1995/ . Accessed 21 Oct 2022.
Nguyen TA, Knight R, Roughead EE, et al. Policy options for pharmaceutical pricing and purchasing: issues for low- and middle-income countries. Health Policy Plan. 2015;30(2):267–80.
doi: 10.1093/heapol/czt105
pubmed: 24425694
Matsumoto T, Tsuchiya T, Hirano T, et al. Changes in the penetration rate of biosimilar infliximab within Japan using a Japanese claims database. Clinicoecon Outcomes Res. 2021;13:145–53.
doi: 10.2147/CEOR.S293698
pubmed: 33658813
pmcid: 7920501
Chambers JD, Lai RC, Margaretos NM, et al. Coverage for biosimilars vs reference products among US commercial health plans. JAMA. 2020;323(19):1972–3.
doi: 10.1001/jama.2020.2229
pubmed: 32427297
pmcid: 7237961
US Department of Health and Human Services. Comprehensive plan for addressing high drug prices: a report in response to the executive order on competition in the American economy. Sep 9 2021. Available from: https://aspe.hhs.gov/reports/comprehensive-plan-addressing-high-drug-prices . Accessed 8 Mar 2023.
Baker JF, Leonard CE, Weisman MH, et al. Biosimilar uptake in academic and Veterans Health Administration settings: influence of institutional incentives. Arthritis Rheumatol. 2020;72(7):1067–71.
doi: 10.1002/art.41277
pubmed: 32253823
pmcid: 7329608
MedPAC. Report to the congress: Medicare and the health care delivery system. June 2021. Available from: https://www.medpac.gov/document/june-2021-report-to-the-congress-medicare-and-the-health-care-delivery-system/ . Accessed 8 Mar 2023.
San-Juan-Rodriguez A, Gellad WF, Good CB, et al. Trends in list prices, net prices, and discounts for originator biologics facing biosimilar competition. JAMA Netw Open. 2019;2(12):e1917379.
doi: 10.1001/jamanetworkopen.2019.17379
pubmed: 31834391
pmcid: 6938676
Bonnett C, Stafinski T, Trindade E. Medicines pricing and reimbursement in Canada. Rev Bras Farm Hosp Serv Saúde. 2022;13(2):811.
doi: 10.30968/rbfhss.2022.132.0811
Verghese NR, Barrenetxea J, Bhargava Y, et al. Government pharmaceutical pricing strategies in the Asia-Pacific region: an overview. J Mark Access Health Policy. 2019;7(1):1601060.
doi: 10.1080/20016689.2019.1601060
pubmed: 31007877
pmcid: 6461095
Godman B, Haque M, Leong T, et al. The current situation regarding long-acting insulin analogues including biosimilars among African, Asian, European, and South American countries; findings and implications for the future. Front Public Health. 2021;9:671961.
doi: 10.3389/fpubh.2021.671961
pubmed: 34249838
pmcid: 8264781
Jensen TB, Bartels D, Sædder EA, et al. The Danish model for the quick and safe implementation of infliximab and etanercept biosimilars. Eur J Clin Pharmacol. 2020;76(1):35–40.
doi: 10.1007/s00228-019-02765-3
pubmed: 31677117
Colloca L, Panaccione R, Murphy TK. The clinical implications of nocebo effects for biosimilar therapy. Front Pharmacol. 2019;10:1372.
doi: 10.3389/fphar.2019.01372
pubmed: 31849647
pmcid: 6895996
Teeple A, Ellis LA, Huff L, et al. Physician attitudes about non-medical switching to biosimilars: results from an online physician survey in the United States. Curr Med Res Opin. 2019;5(4):611–7.
doi: 10.1080/03007995.2019.1571296
Barszczewska O, Piechota A. The impact of introducing successive biosimilars on changes in prices of adalimumab, infliximab, and trastuzumab-Polish experiences. Int J Environ Res Public Health. 2021;18(13):6952.
doi: 10.3390/ijerph18136952
pubmed: 34209612
pmcid: 8297232
IQVIA. Biosimilars in the United States 2020–2024 competition, savings, and sustainability. 2020. Available from: https://www.iqvia.com/insights/the-iqvia-institute/reports/biosimilars-in-the-united-states-2020-2024 . Accessed 8 Mar 2023.